Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
Top Cited Papers
- 1 September 2002
- Vol. 60 (3) , 434-441
- https://doi.org/10.1016/s0090-4295(02)01905-2
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Extracts from "Clinical Evidence": Benign prostatic hyperplasiaBMJ, 2001
- SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 2000
- Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 YearsEuropean Urology, 2000
- EFFECTIVE SUPPRESSION OF DIHYDROTESTOSTERONE (DHT) BY GI198745, A NOVEL, DUAL 5 ALPHA REDUCTASE INHIBITORJournal of Urology, 1999
- A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic ObstructionEuropean Urology, 1999
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- STEROID 5α-REDUCTASE: TWO GENES/TWO ENZYMESAnnual Review of Biochemistry, 1994
- Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.Journal of Clinical Investigation, 1993
- The Effect of Finasteride in Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1992
- Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasiaJournal of Clinical Endocrinology & Metabolism, 1992